Syros Pharmaceuticals, Inc.
(NASDAQ : SYRS)

( )
SYRS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
1.07%200.801.3%$462.93m
BIIBBiogen Inc.
0.09%223.211.3%$371.70m
GILDGilead Sciences, Inc.
-0.47%63.690.9%$361.30m
CELGCelgene Corporation
0.76%100.571.3%$359.89m
ILMNIllumina, Inc.
1.48%302.583.5%$282.38m
REGNRegeneron Pharmaceuticals, Inc.
0.81%300.772.6%$210.74m
EXASExact Sciences Corporation
2.19%92.5024.1%$193.04m
VRTXVertex Pharmaceuticals Incorporated
1.29%172.411.9%$181.51m
ALXNAlexion Pharmaceuticals, Inc.
0.92%99.252.0%$176.54m
AAgilent Technologies, Inc.
1.77%75.311.6%$166.98m
SRPTSarepta Therapeutics, Inc.
0.39%83.4814.6%$138.14m
ALDRAlder Biopharmaceuticals, Inc.
-0.05%18.8710.2%$125.33m
BMRNBioMarin Pharmaceutical Inc.
1.29%67.364.3%$96.05m
ACADACADIA Pharmaceuticals Inc.
0.10%40.5213.4%$95.97m
INCYIncyte Corporation
0.46%76.122.5%$87.99m

Company Profile

Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyse unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. The firm focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines. The company was founded by Richard A. Young, Nathanael S. Gray and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.